BREAKING
Dollar Tree (DLTR) Crushes Q4 Earnings Expectations with $2.56 EPS 8 minutes ago ULTA Stock Plunges 14.2% to $535.72 as Eight Analysts Slash Price Targets After Earnings 11 minutes ago CytomX Therapeutics, Inc. (CTMX) Reports Full Year 2025 Earnings 17 minutes ago Townsquare Media (TSQ) EPS Crushes Estimates by 445.5%, Posts $0.60 vs $0.11 Expected 33 minutes ago VNET Earnings Miss by 99.5% as Revenue Plunges 82.9% to $384.2M in Q4 35 minutes ago Alto Neuroscience (ANRO) Reports FY25 Loss of $2.19/Share 45 minutes ago ANI Pharmaceuticals Insiders Unload $584K in Shares Amid 18-Month Selling Streak 51 minutes ago Niu Technologies (NIU) Reports Loss for Q4 2025; Revenue Drops to $96.7M 1 hour ago Townsquare Media, Inc. (TSQ) Beats Q4 EPS Estimates 1 hour ago Century Aluminum’s (CENX) Kenneth Calloway Sells 18K Shares Amid Insider Selling Spree 1 hour ago Dollar Tree (DLTR) Crushes Q4 Earnings Expectations with $2.56 EPS 8 minutes ago ULTA Stock Plunges 14.2% to $535.72 as Eight Analysts Slash Price Targets After Earnings 11 minutes ago CytomX Therapeutics, Inc. (CTMX) Reports Full Year 2025 Earnings 17 minutes ago Townsquare Media (TSQ) EPS Crushes Estimates by 445.5%, Posts $0.60 vs $0.11 Expected 33 minutes ago VNET Earnings Miss by 99.5% as Revenue Plunges 82.9% to $384.2M in Q4 35 minutes ago Alto Neuroscience (ANRO) Reports FY25 Loss of $2.19/Share 45 minutes ago ANI Pharmaceuticals Insiders Unload $584K in Shares Amid 18-Month Selling Streak 51 minutes ago Niu Technologies (NIU) Reports Loss for Q4 2025; Revenue Drops to $96.7M 1 hour ago Townsquare Media, Inc. (TSQ) Beats Q4 EPS Estimates 1 hour ago Century Aluminum’s (CENX) Kenneth Calloway Sells 18K Shares Amid Insider Selling Spree 1 hour ago
ADVERTISEMENT
Breaking News

CytomX Therapeutics, Inc. (CTMX) Reports Full Year 2025 Earnings

Q4 2025 loss at CytomX Therapeutics, Inc. (CTMX) widened to $0.20 per share GAAP, worse than the -$0.09 estimate (116.4% wider).

$CTMX
March 16, 2026 1 min read

Q4 2025 loss at CytomX Therapeutics, Inc. (CTMX) widened to $0.20 per share GAAP, worse than the -$0.09 estimate (116.4% wider).

A detailed analysis of CytomX Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.

Related: ACIU: AC Immune (ACIU) Q4 Loss Narrows to $0.14/Share vs $0.17 Estimate, Revenue Plunges 70.3% | XBIO: Xenetic Biosciences (XBIO) Reports Narrower Q4 Loss of $0.22/Share, Beating $0.52 Estimate by 57.7% | SVRA: Savara (SVRA) Reports Q4 Loss of $0.13 Per Share, Flat Year-Over-Year | BRNS: Barinthus Biotherapeutics (BRNS) Q4 Loss Widens 711.5% YoY to $1.64 Per Share | NKTR: Nektar (NKTR) Swings to $0.03 EPS Profit, Issues $540M-$555M Revenue Guidance for 2026 | Full CTMX analysis on AlphaStreet

ADVERTISEMENT
Tags: #CTMX

Related Articles